13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001009258
Total reported value
$9.6B
$9.6B
433 檔
24.4%
According to the latest 13F quarterly dataset, Deerfield Management Company, L.p. managed an equity portfolio of $9.6B at the end of Q2 2024, spanning 433 distinct U.S. exchange-listed positions.
In Q2 2024, Deerfield Management Company, L.p. displayed an active expansion posture, initiating 10 new positions and adding to 17 existing holdings, outstripping position reductions.
Showing top 200 holdings (of 433 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 25.23% | +1.37% | — | |
| 2 | INSM 1.75 01-15-25Bond | Insmed Inc | Bond | 4.30% | — | +29.46% | |
| 3 | VTRS | Viatris Inc | Stock-Healthcare | 3.78% | +0.13% | +0.00% | |
| 4 | CNC | Centene CORP | Stock-Healthcare | 2.92% | +0.99% | +11.30% | |
| 5 | IART 0.5 08-15-25Bond | Integra Lifesciences Hld | Bond | 2.74% | — | +68.93% | |
| 6 | BKD 2 10-15-26Bond | Brookdale Senior Living | Bond | 2.72% | — | — | |
| 7 | ✓ | Merus N V | Stock-Other | 2.71% | — | +3.77% | |
| 8 | LRMR | Larimar Therapeutics Inc | Stock-Other | 2.56% | -0.76% | — | |
| 9 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 2.35% | -1.15% | EXIT | |
| 10 | AHCO | Adapthealth CORP | Stock-Other | 2.21% | -0.36% | — | |
| 11 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.00% | +2.03% | — | |
| 12 | ACCD 0.5 04-01-26Bond | Accolade Inc | Bond | 1.92% | — | — | |
| 13 | SGRY | Surgery Partners Inc | Stock-Other | 1.86% | — | +47.71% | |
| 14 | KURA | Kura Oncology Inc | Stock-Other | 1.85% | — | — | |
| 15 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 1.83% | — | -25.75% | |
| 16 | BKD | Brookdale Senior Living Inc | Stock-Other | 1.77% | +0.07% | — | |
| 17 | WAY | Waystar Holding CORP | Stock-Other | 1.77% | — | — | |
| 18 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.70% | — | — | |
| 19 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.58% | -0.95% | EXIT | |
| 20 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.57% | -0.08% | — | |
| 21 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | Bond | 1.56% | -2.47% | EXIT | |
| 22 | ACH | Accendra Health Inc | Stock-Other | 1.43% | — | +30.63% | |
| 23 | ALHC | Alignment Healthcare Inc | Stock-Other | 1.42% | — | +31.81% | |
| 24 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.23% | +0.46% | -20.27% | |
| 25 | ✓ | Hillevax Inc | Stock-Other | 0.96% | — | — | |
| 26 | CVS | Cvs Health CORP | Stock-Healthcare | 0.96% | — | — | |
| 27 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.95% | -0.06% | EXIT | |
| 28 | BAX | Baxter International Inc | Stock-Healthcare | 0.88% | — | +25590.39% | |
| 29 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.86% | — | — | |
| 30 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.84% | -0.12% | +62.88% | |
| 31 | BNTX | Biontech Se-adr | Stock-Other | 0.79% | — | +4.29% | |
| 32 | IRON | Disc Medicine Inc | Stock-Other | 0.77% | — | +53.75% | |
| 33 | EHABUSD | Enhabit Inc | Stock-Other | 0.74% | -0.79% | EXIT | |
| 34 | CNMD | Conmed CORP | Stock-Other | 0.73% | — | +86.67% | |
| 35 | IART | Integra Lifesciences Holding | Stock-Other | 0.71% | — | -0.37% | |
| 36 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 0.69% | -0.05% | -0.44% | |
| 37 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.67% | -0.94% | EXIT | |
| 38 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.58% | — | — | |
| 39 | EMBC | Embecta CORP | Stock-Healthcare | 0.57% | -0.17% | — | |
| 40 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.55% | +0.17% | -18.31% | |
| 41 | COGT | Cogent Biosciences Inc | Stock-Other | 0.53% | -2.09% | +144.03% | |
| 42 | LNTH 2.625 12-15-27Bond | Lantheus Holdings Inc | Bond | 0.52% | — | — | |
| 43 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.48% | -0.06% | — | |
| 44 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 45 | PHVS | Pharvaris N.V. | Stock-Other | 0.44% | +0.18% | +31.62% | |
| 46 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.40% | — | — | |
| 47 | PODD | Insulet CORP | Stock-Healthcare | 0.38% | — | +2.16% | |
| 48 | NKTX | Nkarta Inc | Stock-Other | 0.37% | — | -26.86% | |
| 49 | DCGO | Docgo Inc | Stock-Other | 0.37% | — | +40.98% | |
| 50 | INMD | InMode Ltd. | Stock-Other | 0.35% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM 1.75 01-15-25Bond | Insmed Inc | +2.1% | +29.46% | Add |
| 2 | WAY | Waystar Holding CORP | +1.8% | NEW | New buy |
| 3 | GILD | Gilead Sciences Inc | +1.7% | NEW | New buy |
| 4 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | +1.6% | NEW | New buy |
| 5 | IART 0.5 08-15-25Bond | Integra Lifesciences Hld | +1% | +68.93% | Add |
| 6 | CVS | Cvs Health CORP | +1% | NEW | New buy |
| 7 | BAX | Baxter International Inc | +0.9% | +25590.39% | Add |
| 8 | ALHC | Alignment Healthcare Inc | +0.7% | +31.81% | Add |
| 9 | ✓ | Merus N V | +0.6% | +3.77% | Add |
| 10 | CGEM | Cullinan Therapeutics Inc | +0.6% | +188.11% | Add |
| 11 | ALNY | Alnylam Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 12 | CATX | Perspective Therapeutics Inc | +0.5% | NEW | New buy |
| 13 | BCRX | Biocryst Pharmaceuticals Inc | +0.4% | +62.88% | Add |
| 14 | MREO | Mereo Biopharma Group Pl-adr | +0.4% | NEW | New buy |
| 15 | COGT | Cogent Biosciences Inc | +0.4% | +144.03% | Add |
| 16 | PACS | Pacs Group Inc | +0.3% | NEW | New buy |
| 17 | RVMD | Revolution Medicines Inc | +0.3% | — | Unchanged |
| 18 | CNMD | Conmed CORP | +0.3% | +86.67% | Add |
| 19 | FHTX | Foghorn Therapeutics Inc | +0.2% | NEW | New buy |
| 20 | SGRY | Surgery Partners Inc | +0.2% | +47.71% | Add |
| 21 | TXG | 10x Genomics Inc-class A | +0.2% | NEW | New buy |
| 22 | CGON | Cg Oncology Inc | +0.2% | +811.95% | Add |
| 23 | DAWNGBX | Day One Biopharmaceuticals I | +0.2% | +65.59% | Add |
| 24 | AUTL | Autolus Therapeutics PLC | -0.2% | — | Unchanged |
| 25 | LKFT | Lakefront Biotherapeutic-adr | -0.2% | — | Unchanged |
| 26 | ACCDUSD | Accolade Inc | -0.2% | +45.88% | Add |
| 27 | GPCR | Structure Therapeutics Inc | -0.2% | -18.31% | Trim |
| 28 | BIO | Bio-rad Laboratories-a | -0.2% | -0.44% | Trim |
| 29 | ✓ | Engene Holdings Inc | -0.2% | EXIT | Sold out |
| 30 | EHABUSD | Enhabit Inc | -0.3% | — | Unchanged |
| 31 | GH | Guardant Health Inc | -0.3% | EXIT | Sold out |
| 32 | QDEL | Quidelortho CORP | -0.3% | EXIT | Sold out |
| 33 | CABA | Cabaletta Bio Inc | -0.3% | -63.12% | Trim |
| 34 | VSTM | Verastem Inc | -0.3% | EXIT | Sold out |
| 35 | CNC | Centene CORP | -0.3% | +11.30% | Add |
| 36 | SLDB | Solid Biosciences Inc | -0.4% | -22.87% | Trim |
| 37 | KYTX | Kyverna Therapeutics Inc | -0.4% | +35.60% | Add |
| 38 | SPRY | Ars Pharmaceuticals Inc | -0.4% | — | Unchanged |
| 39 | AHCO | Adapthealth CORP | -0.4% | — | Unchanged |
| 40 | ISREUR | Isoray Inc | -0.6% | EXIT | Sold out |
| 41 | OSCR | Oscar Health Inc - Class A | -0.6% | -25.75% | Trim |
| 42 | NKTX | Nkarta Inc | -0.6% | -26.86% | Trim |
| 43 | VKTX | Viking Therapeutics Inc | -0.7% | EXIT | Sold out |
| 44 | VTRS | Viatris Inc | -0.7% | +0.00% | Add |
| 45 | IDYA | Ideaya Biosciences Inc | -0.8% | -20.27% | Trim |
| 46 | NUVL | Nuvalent Inc-a | -0.9% | — | Unchanged |
| 47 | ACH | Accendra Health Inc | -0.9% | +30.63% | Add |
| 48 | SWTXUSD | Springworks Therapeutics Inc | -1.1% | EXIT | Sold out |
| 49 | DCPHEUR | Deciphera Pharmaceuticals In | -1.4% | EXIT | Sold out |
| 50 | ✓ | Fusion Pharmaceuticals Inc | -2.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Deerfield Management Company, L.p. reported a total U.S. public equity portfolio value of $9.6B across 433 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, INSM 1.75 01-15-25, VTRS) accounted for 24.4% of total reported equity market value during Q2 2024.
Top New Position Initiated
WAY
市值: $106.5M
Top Position Liquidated / Trimmed
FUSION PHARMACEUTICALS INC
前期市值: $136.5M
During Q2 2024, Deerfield Management Company, L.p.'s top holdings by market value included NUVL (25.2%)、INSM 1.75 01-15-25 (4.3%)、VTRS (3.8%). The largest single position, NUVL, represented 25.2% of total portfolio value.
In Q2 2024, Deerfield Management Company, L.p. made 43 total portfolio adjustments, initiating 10 new buys, adding to 17 positions, trimming 7 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.